体内沉默肠道DMT1减轻中间型β地中海贫血(Hbbth3/+)小鼠的铁负荷
本研究在中间型β地中海贫血(βTI)小鼠模型Hbbth3/+中,通过肠道特异性敲除DMT1证实其是铁吸收和铁负荷所必需;进一步用姜来源脂质纳米粒包裹DMT1特异性siRNA每日灌胃4周龄Hbbth3/+小鼠16天,DMT1表达降低>80%,肝脏铁和血清铁蛋白显著降低,提示肠道DMT1是减轻βTI铁过载的潜在治疗靶点。
要点
- 肠道DMT1敲除使Hbbth3/+小鼠从铁过载转为铁缺乏表型并加重贫血,表明DMT1是铁吸收和铁负荷所必需。
- 口服姜来源脂质纳米粒包裹DMT1特异性siRNA每日灌胃16天,使DMT1表达降低>80%。
- siRNA治疗显著降低肝脏铁和血清铁蛋白,提示肠道DMT1是减轻βTI铁过载的潜在治疗靶点。
核心结论
- 肠道DMT1是Hbbth3/+小鼠铁吸收和铁负荷所必需,体内敲低肠道DMT1可减轻铁负荷,提示其是减轻βTI铁过载的潜在治疗靶点。
研究设计与样本
- 将中间型β地中海贫血临床前模型Hbbth3/+小鼠与肠道特异性DMT1敲除小鼠杂交。
- 用姜来源脂质纳米粒包裹DMT1特异性或对照siRNA,对4周龄Hbbth3/+小鼠每日灌胃给药16天。
主要发现
- Hbbth3/+小鼠肠道DMT1敲除后出现从铁过载向铁缺乏表型的病理生理转变,贫血加重。
- siRNA治疗使DMT1表达降低>80%。
- siRNA治疗使肝脏铁和血清铁蛋白显著降低,二者反映体内铁储存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
β-thalassemia is an iron-loading anemia caused by homozygous mutation of the hemoglobin subunit β (HBB) gene. In β-thalassemia intermedia (βTI), a non-transfusion-dependent form of the disease, iron overload is caused by excessive absorption of dietary iron due to inappropriately low production of the iron-regulatory hormone hepcidin. Low hepcidin stabilizes the iron exporter ferroportin (FPN) on the basolateral membrane of enterocytes. High FPN activity may deplete intracellular iron and enhance expression of the predominant iron importer divalent metal-ion transporter 1 (DMT1). In mice, DMT1 mediates normal iron absorption under physiological conditions and excessive iron absorption in pathological iron overload (eg, hereditary hemochromatosis). Here, we hypothesized that DMT1 drives elevated iron absorption in βTI. Accordingly, we crossed Hbbth3/+ mice, a preclinical model of βTI, with intestine-specific DMT1-knockout mice. Ablation of intestinal DMT1 in Hbbth3/+ mice caused a pathophysiological shift from iron overload to an iron-deficiency phenotype with exacerbated anemia. DMT1 is thus required for iron absorption and iron loading in Hbbth3/+ mice. Based upon these outcomes, we further logically postulated that in vivo knockdown of intestinal DMT1 would mitigate iron loading in Hbbth3/+ mice. Ginger-derived, lipid nanoparticles carrying DMT1-specific (or control) small interfering RNAs (siRNAs) were administered by oral, intragastric gavage to 4-week-old Hbbth3/+ mice daily for 16 days. siRNA treatment reduced DMT1 expression by >80% and blunted iron loading, as indicated by significant reductions in liver iron and serum ferritin (which reflect body iron stores). These notable experimental outcomes establish intestinal DMT1 as a plausible therapeutic target to mitigate iron overload in βTI.
引用
- Yu Y, Woloshun RR, Lee JK, et al. In vivo silencing of intestinal DMT1 mitigates iron loading in β-thalassemia intermedia (Hbbth3/+) mice. Blood Adv. 2024. PMID: 39250719. doi:10.1182/bloodadvances.2024013333
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。